Overview

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Phase 1 single dose study of ALXN1101 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Alexion Pharma GmbH
Origin Biosciences
Treatments:
Molybdenum